The ‘Ozempic effect’ hits worldwide share market

obesity: overweight person holds bulge over hip
Whether health industry or junk food business, steamroller popularity of weight loss drug shakes up stock prices The huge success of the new wave of GLP-1 (glucagon-like peptide-1) receptor agonist drugs such as market leader Ozempic has had a massive and, many argue, completely overblown effect on share prices in the world’s financial markets over

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild Super acquired by ethical super umbrella group
Next Key services on ‘chopping block’ for 8CPA